Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Tosikyan, A."'
Autor:
Alexander Lesokhin, Richard LeBlanc, Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al‐Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van deVelde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé, Philippe Moreau
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10254-10266 (2023)
Abstract Background Given the incurable nature of multiple myeloma (MM), efforts are made to improve the efficacy of anti‐CD38 monoclonal antibodies via combinations with other potentially synergistic therapies. This Phase 1/2 trial (NCT03194867) w
Externí odkaz:
https://doaj.org/article/5e8923e3821746dba211ec639b02c19b
Autor:
Anne-Laure Lapeyraque, Martin Bitzan, Imad Al-Dakkak, Mira Francis, Shih-Han S. Huang, Roger Kaprielian, Loree Larratt, Katerina Pavenski, Christine Ribic, Axel Tosikyan, Christoph Licht, David Philibert
Publikováno v:
Canadian Journal of Kidney Health and Disease, Vol 7 (2020)
Background: Atypical hemolytic uremic syndrome (aHUS) is an extremely rare, heterogeneous disease of uncontrolled activation of the alternative complement pathway that is difficult to diagnose. We have evaluated the Canadian patients enrolled in the
Externí odkaz:
https://doaj.org/article/f5abb0f45f7045dab2ce21463229fe09
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Assouline, Sarit E., Nielsen, Torsten Holm *, Yu, Stephen *, Alcaide, Miguel, Chong, Lauren, MacDonald, David, Tosikyan, Axel, Kukreti, Vishal, Kezouh, Abbas, Petrogiannis-Haliotis, Tina, Albuquerque, Marco, Fornika, Daniel, Alamouti, Sepideh, Froment, Remi, Greenwood, Celia M.T., Oros, Kathleen Klein, Camglioglu, Errol, Sharma, Ayushi, Christodoulopoulos, Rosa, Rousseau, Caroline, Johnson, Nathalie, Crump, Michael, Morin, Ryan D., Mann, Koren K.
Publikováno v:
In Blood 14 July 2016 128(2):185-194
Autor:
Nathalie A. Johnson, Koren K. Mann, Roujun Peng, Qiang Pan-Hammarstrom, André Constantin, Errol Camlioglu, Madeleine Arseneault, Yasser Riazalhosseini, Celia Greenwood, Kathleen Klein Oros, Yury Monczak, Marco Albuquerque, Remi Froment, Pierre Sesques, Maryam Bayat, Caroline Rousseau, David MacDonald, Bruno M. Grande, Axel Tosikyan, Michael Crump, Tina Petrogiannis-Haliotis, Torsten Holm Nielsen, Kevin Bushell, Daniel Fornika, Stephen Yu, Jasleen Grewal, Lauren Chong, Rebecca L. Johnston, Arezoo Mohajeri, Miguel Alcaide, Sarit Assouline, Ryan D. Morin
Targeted sequencing of untreated DLBCL and TLy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a9c59a40d78b04064035f89483a3ac
https://doi.org/10.1158/1078-0432.22457204.v1
https://doi.org/10.1158/1078-0432.22457204.v1
Autor:
Nathalie A. Johnson, Koren K. Mann, Roujun Peng, Qiang Pan-Hammarstrom, André Constantin, Errol Camlioglu, Madeleine Arseneault, Yasser Riazalhosseini, Celia Greenwood, Kathleen Klein Oros, Yury Monczak, Marco Albuquerque, Remi Froment, Pierre Sesques, Maryam Bayat, Caroline Rousseau, David MacDonald, Bruno M. Grande, Axel Tosikyan, Michael Crump, Tina Petrogiannis-Haliotis, Torsten Holm Nielsen, Kevin Bushell, Daniel Fornika, Stephen Yu, Jasleen Grewal, Lauren Chong, Rebecca L. Johnston, Arezoo Mohajeri, Miguel Alcaide, Sarit Assouline, Ryan D. Morin
Purpose: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of patients, and yet little is known about its biology.Experimental Design: Using exome sequencing, we characterized the mutation profiles of 38 rrDLBCL biopsies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23d8e7088123c06fa1735170d51d9bdc
https://doi.org/10.1158/1078-0432.c.6523535.v1
https://doi.org/10.1158/1078-0432.c.6523535.v1
Autor:
Nathalie A. Johnson, Koren K. Mann, Roujun Peng, Qiang Pan-Hammarstrom, André Constantin, Errol Camlioglu, Madeleine Arseneault, Yasser Riazalhosseini, Celia Greenwood, Kathleen Klein Oros, Yury Monczak, Marco Albuquerque, Remi Froment, Pierre Sesques, Maryam Bayat, Caroline Rousseau, David MacDonald, Bruno M. Grande, Axel Tosikyan, Michael Crump, Tina Petrogiannis-Haliotis, Torsten Holm Nielsen, Kevin Bushell, Daniel Fornika, Stephen Yu, Jasleen Grewal, Lauren Chong, Rebecca L. Johnston, Arezoo Mohajeri, Miguel Alcaide, Sarit Assouline, Ryan D. Morin
Supplemental methods Supplemental Figures Supplemental Figure S1. Overview of somatic copy number alterations in rrDLBCLs. Supplemental Figure S2. Consistent low coverage in the first exon of FOXO1. Supplemental Figure S3. Overview of FOXO1 mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e738e5bf485353639537fe6157e232
https://doi.org/10.1158/1078-0432.22457213
https://doi.org/10.1158/1078-0432.22457213
Autor:
Meletios A. Dimopoulos, Matthew C. Cheung, Murielle Roussel, Ting Liu, Barbara Gamberi, Brigitte Kolb, H. Guenter Derigs, HyeonSeok Eom, Karim Belhadj, Pascal Lenain, Richard Van der Jagt, Sophie Rigaudeau, Mamoun Dib, Rachel Hall, Henry Jardel, Arnaud Jaccard, Axel Tosikyan, Lionel Karlin, William Bensinger, Rik Schots, Nicolas Leupin, Guang Chen, Jennifer Marek, Annette Ervin-Haynes, Thierry Facon
Publikováno v:
Haematologica, Vol 101, Iss 3 (2016)
Renal impairment is associated with poor prognosis in myeloma. This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal im
Externí odkaz:
https://doaj.org/article/c7d7ee8abeb3409b82ff48e5ea23ff7d
Autor:
Nizar J. Bahlis, Thierry Facon, Matthew C. Cheung, Axel Tosikyan, Kevin W. Song, Andrew Belch, Christine Chen, Darrell White, Kenneth C. Anderson, Shankar Srinivasan, Suzanne Robinson, Angela Dispenzieri, Chaim Shustik, Diane Brown
Publikováno v:
Cancer Medicine
The phase 3 FIRST trial demonstrated significant improvement in progression‐free survival (PFS) and overall survival (OS) with an immune‐stimulatory agent, lenalidomide, in combination with low‐dose dexamethasone until disease progression (Rd c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::375d9016da5b7e01ff71255f59c8da39
https://doi.org/10.1002/cam4.3511
https://doi.org/10.1002/cam4.3511
Autor:
Katerina Pavenski, Axel Tosikyan, Shih-Han S. Huang, David Philibert, Martin Bitzan, Loree Larratt, Christine Ribic, Mira Francis, Christoph Licht, Anne-Laure Lapeyraque, Imad Al-Dakkak, Roger Kaprielian
Publikováno v:
Canadian Journal of Kidney Health and Disease
Canadian Journal of Kidney Health and Disease, Vol 7 (2020)
Canadian Journal of Kidney Health and Disease, Vol 7 (2020)
Atypical hemolytic uremic syndrome (aHUS) is an extremely rare, heterogeneous disease of uncontrolled activation of the alternative complement pathway that is difficult to diagnose. We have evaluated the Canadian patients enrolled in the Global aHUS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc841b89127f3cfdb61db53442e4cc75
http://europepmc.org/articles/PMC6984425
http://europepmc.org/articles/PMC6984425